Shanghai-based biotech Allist Pharmaceuticals Co., Ltd has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its furmonertinib as an adjuvant therapy for stage IB-IIIB non-small cell lung cancer (NSCLC) carrying non-classical epidermal growth factor receptor (EGFR) mutations. The study will evaluate the drug’s efficacy in patients undergoing radical resection with or without adjuvant chemotherapy.
Clinical Study Background
Approximately 30% of NSCLC patients with indications are diagnosed as stage I-IIIB resectable NSCLC, with surgical radical resection being the preferred treatment option. Despite having a better prognosis compared to late-stage patients, those who undergo only surgical treatment still face a lower 5-year survival rate according to the indications. This underscores the need for effective adjuvant therapies like furmonertinib to improve outcomes.
Furmonertinib: Drug Profile
Allist’s in-house discovery furmonertinib is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor. It is being co-developed in territories outside of Greater China with ArriVent under a 2021 deal. The drug features strong brain penetration, excellent therapeutic effects, good safety, and a wide treatment window. Furmonertinib is covered by China’s National Reimbursement Drug List (NRDL) for second-line and first-line indications, highlighting its potential to address significant unmet medical needs in NSCLC treatment.-Fineline Info & Tech
